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Open access uBackground: Tribbles homolog 3 (TRIB3) is a pseudokinase involved in the regulation of several signaling
pathways involved in cell survival and/or cell stress. Here, we determined the correlation between breast
cancer prognosis and TRIB3 protein levels and established the role of TRIB3 in cell survival after hypoxia
and/or radiotherapy.
Material and methods: TRIB3 mRNA and protein were quantiﬁed in a new independent breast cancer
patient cohort using QPCR and a new speciﬁc avian antibody against TRIB3. In addition, we used
siRNA-mediated knockdown of TRIB3 in a colony-forming assay after hypoxia and radiotherapy.
Results: TRIB3 mRNA and protein levels did not correlate in breast cancer cell lines or human breast can-
cer material. We validated our earlier ﬁnding that high TRIB3 mRNA denotes a poor prognosis, but found
that high TRIB3 protein levels were associated with a good prognosis in breast cancer patients. We also
show that knockdown of TRIB3 resulted in an increased survival under hypoxic conditions.
Conclusion: Whereas mRNA levels of TRIB3 are related with a poor prognosis, TRIB3 protein is associated
with a good prognosis in human breast cancer patients, possibly due to the fact that TRIB3 is involved in
hypoxia tolerance.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 101 (2011) 198–202Tribbles homolog 3 (TRIB3) is one of three human homologs of
the Drosophila cell cycle inhibitor tribbles [1,2]. TRIB3 is induced by
ER stress [3], hypoxia [4], and nutrient starvation [5], all of which
are potentially related to treatment resistance. This cell stress in-
duced upregulation of TRIB3 is mediated via the unfolded protein
response (UPR), more speciﬁcally via the transcriptional regulators
ATF4 and CHOP [6]. The UPR is likely to be involved in therapy
resistance of tumor cells, especially under hypoxic conditions
[7–11]. TRIB3 functions as a negative feedback regulator of the
ATF4/CHOP pathway [6,12,13]. TRIB3 is also known to inhibit
phosphorylation of AKT/Protein Kinase B (AKT) [14]. AKT is a phos-
phoinositide-dependent serine/threonine protein kinase that plays
a critical role in the signal transduction of growth factor receptors.
There is abundant evidence that the PI3-kinase/AKT pathway is
central in determining the sensitivity of solid tumors to ionizing
radiation, chemotherapy and possibly to endocrine therapy
[15–19]. In addition, all three human homologs of tribbles bind
mitogen-activated protein kinase-kinases (MAPKKs) and regulate
the activation of MAP-kinase pathways by serving as scaffold pro-
teins [20]. These intracellular signaling pathways are relevant foradiation Oncology, Radboud
1, 6500 HB Nijmegen, The
. Wennemers).
nder the Elsevier OA license.tumor growth and treatment resistance [21,22]. However, how
TRIB3 is involved in tumor progression and/or treatment resistance
is unclear, as both cytoprotective [13] as well as pro-apoptotic
roles of TRIB3 [6] have been described.
Recently, we found that TRIB3 mRNA denoted a poor prognosis
in breast cancer patients (Wennemers et al., submitted), suggesting
that the involvement of TRIB3 in the UPR and/or growth factor
receptor signaling results in an association with disease progres-
sion and/or treatment resistance. Here, we set out to validate these
results in an independent patient cohort, and to extent the data by
speciﬁc immunohistochemical staining of TRIB3 protein and by
siRNA mediated knockdown in radiation experiments.Material and methods
Patients samples
Breast cancer patients were selected from a cohort surgically
treated between January 1991 and December 1996 that had no ax-
illary lymph node invasion, received no adjuvant systemic treat-
ment, and had at least 5 years follow up or a recurrence before
that. The selection criteria led to a patient cohort with 25% ER po-
sitive, 13% PR positive, 30% HER2-positive, and 44% triple negative
patients. As approved by the institutional review board and
according to national law, coded tumor tissues were used.
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Total RNA was isolated and reverse transcriptase was per-
formed as described earlier (Wennemers et al., submitted). For pa-
tient material an adjacent slice was H&E stained to determine
tumor percentage. cDNAs were ampliﬁed with TRIB3-speciﬁc prim-
ers (forward: att agg cag ggt ctg tcc tgt g, reverse: agt atg gac ctg
gga ttg tgg a) using Sybr Green Master Mix (Applied Biosystems,
Nieuwerkerk a/d lJssel, The Netherlands) on an ABI Prism 7700 Se-
quence detection system (Applied Biosystems). All samples were
normalized for levels of hypoxanthine–guanine phosphoribosyl-
transferase (HPRT) expression.
TRIB3 antibody development
Chickens and rabbits were immunized with three different LPH
conjugated peptides from different parts of the human TRIB3 pro-
tein sequence obtained from Biogenes GmbH (Berlin, Germany).







CRFVFADRERKKLVLENL203 and peptide 3: and
3380DGLGLDEAREEEGDREVV355
0
. The experimental design was ap-
proved by the Animal Ethics Committee of the Radboud University
Nijmegen and described earlier [23]. Polyclonal antibodies isolated
from chicken egg yolks and citrate plasmas from rabbits were puri-
ﬁed by afﬁnity chromatography against the peptides in question.
Further characterization was done with one side ELISA and Wes-
tern blotting techniques.
TRIB3 Western blot analysis
Breast cancer cells (LGC Promochem, London, UK) were har-
vested in RIPA buffer with phosphatase and protease inhibitors
(Roche, Indianapolis, IN). Thirty microgram of protein was fraction-
ated on 12% Criterion XT Bis–Tris gels (Bio-Rad Laboratories B.V.,
Veenendaal, The Netherlands). Samples were transferred to PVDF
membranes (Millipore Immobilon, Millipore, Bedford, MA), and
incubated with chicken anti-TRIB3 peptide 3 or rabbit-anti-b-actin
IgG (#4970, Cell Signaling Technology, Beverly, MA). Proteins were
detected using chemiluminescent peroxidase substrate (Sigma–Al-
drich, St. Louis, MO, USA) and visualized with a ChemiDoc
XRS + imaging system (Bio-Rad Laboratories B.V.). Images and pro-
tein band intensities were acquired using Quantity One 1-D Anal-
ysis Software (Bio-Rad Laboratories B.V.).
Tissue microarray
Hematoxylin and eosin (HE) stained 4 lm sections of formalin-
ﬁxed parafﬁn-embedded tumor sections were used to identify tu-
mor areas by an experienced pathologist. The tumor areas were
outlined on the glass slides and used to select the appropriate area
in the tissue blocks to punch out tissue (2 mm ø) for the tissue
microarrays (TMA) using a Tissue-Tek Quick Ray puncher (Sakura
Finetek Europe B.V., Leiden, The Netherlands). Four lm thick sec-
tions of the TMAwere incubated with chicken anti-TRIB3, and don-
key anti-chicken biotin labeled secondary antibody (Jackson
ImmunoResearch Europe Ltd., Suffolk, UK), followed by incubation
with ABC reagent and visualization with DAB reagent (Vector Lab-
oratories Ltd., Peterborough, UK). Sections were counterstained
with Mayer0s hematoxylin solution. Negative control included sub-
stitution of the primary antibody with primary antibody diluent
(PAD, AbD serotec, Oxford, UK).
Colony forming assay
A colony forming assay was performed to determine cell sur-
vival [24]. Knockdown of TRIB3 was performed in MDA-MB-231
cells using siRNA transfection reagent SAINT-RED (Synvolux Ther-
apeutics B.V., Groningen, The Netherlands). siRNA0s MISSION siR-NA Universal Negative Control #1 (SIC001), TRIB3 (1)
(SASI_Hs01_00197511) and TRIB3 (2) (SASI_Hs01_00197513) were
acquired from Sigma–Aldrich. After transfection the cells were
seeded in 6-well plates and normoxic or hypoxic incubation
(0.1% O2, H35 hypoxystation, Don Whitley Scientiﬁc Ltd., West
Yorkshire, UK) started 24 h before radiation with 4 Gy. Before irra-
diation, cells were sealed under hypoxia, therefore, the hypoxic
status of the cells was unchanged during irradiation. Directly after
irradiation cells were transferred back into the hypoxic chamber.
Hypoxic incubation continued for 24 h, after which all plates were
cultured under standard culture conditions for 1 week to divide
and form colonies. After ﬁxation with 70% EtOH the cells were
stained with 0.5% w/v Crystal Violet and colonies were counted
using a ChemiDoc XRS + imaging system in combination with
Quantity One 1-D Analysis Software (Bio-Rad Laboratories B.V.).Statistical analysis
Statistical analyses were carried out using SPSS 16.0 software
(SPSS Benelux BV, Gorinchem, The Netherlands). Normality of dis-
tribution of variables was tested using Kolmogorov–Smirnov test-
ing. Equality of distribution of patient characteristic, biological
markers and treatment among different TRIB3 groups was tested
using the v2 test. Non-parametric correlations were established
using Spearman Rank correlation testing. Disease free survival
(DFS) time (deﬁned as the time from surgery until diagnosis of
recurrent or metastatic disease) and overall survival (OS) time (de-
ﬁned as the time between date of surgery and death by any cause)
were used as follow-up endpoints. Survival curves were generated
using the method of Kaplan and Meier. Equality of survival distri-
butions was tested using log-rank testing and using Cox univariate
regression analyses. Two-sided P-values below 0.05 were consid-
ered statistically signiﬁcant.Results
TRIB3 mRNA correlates with breast cancer prognosis
To validate our earlier results, TRIB3 mRNA expression levels
were measured in an independent patient cohort. In these patients
(n = 95), TRIB3 mRNA levels were signiﬁcantly higher in tumors
with a triple negative phenotype (P = 0.004) compared to the other
breast cancer subtypes. After dichotomizing patients based on the
median expression level of TRIB3 mRNA in the tumor, the group
with low TRIB3 mRNA expression had a DFS of 133 (CI = 121–
144) months whereas the group with high TRIB3 mRNA expression
had a DFS of 109 (CI = 92–125) months (P = 0.016) (Supplementary
Fig. 1).Development of TRIB3 antibody
Commercially available antibodies for TRIB3 showed multiple,
non-speciﬁc, bands on Western blot of both cell lines and tumor
tissue (Supplementary Fig. 2A). Therefore, we developed our own
TRIB3 antibodies. Three pairs of chickens and three pairs of rabbits
were immunized with three different peptides. Primary character-
ization of all antibodies was done using one-sided ELISA with
plates coated with original unconjugated peptides and none of
the peptides showed a cross reaction with the other peptides used
(Supplementary Fig. 2B). Antibodies against peptide 2 gave lower
titers than peptides 1 and 3 in all animals. After afﬁnity puriﬁca-
tion, the antibodies against peptides 1 and 3 were tested according
to a previously described two-sided ELISA format [25]. A commer-
cially available TRIB3 lysate was used as a standard. These ELISA’s
generated clear dose–response curves (Supplementary Fig. 2C).
Further speciﬁcity testing was performed using Western blotting
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Fig. 1. No correlation of TRIB3 protein and mRNA. (A) Western blot of six breast cancer cell lines protein lysates stained for TRIB3 and b-actin as a loading control. (B) TRIB3
mRNA (±SD) and protein expression plotted for six breast cancer cell lines. (C) TRIB3 mRNA expression plotted for breast cancer patients divided into three different
categories based on the TRIB3 protein levels. 0 = negative, 1 = weakly positive, and 3 = strongly positive stained for TRIB3 protein.
200 TRIB3 protein and breast cancer prognosistechniques. The antibody from the chicken immunized with
peptide 3 gave a clear and predominant band at 48 kDa (Supple-
mentary Fig. 2D). This antibody was further used for immunohisto-
chemical staining and Western blot analyses to determine TRIB3
protein levels.Expression levels of protein and mRNA of TRIB3 do not correlate
With the availability of an antibody for TRIB3 we tested the cor-
relation between TRIB3 mRNA and protein expression in six hu-
man breast cancer cell lines using QPCR, and Western blotting
(Fig. 1A). No correlation was found between RNA and protein levels
of TRIB3 (Fig. 1B). Next, we quantiﬁed TRIB3 protein expression
levels in our cohort of human breast cancer material on the TMA
and compared this with TRIB3 mRNA expression levels. TRIB3 pro-
tein expression was scored as negative (n = 45), weakly positive
(n = 58) or strongly positive (n = 18) (Fig. 2). Here, TRIB3 protein
levels did also not correlate with TRIB3 mRNA levels (Fig. 1C, cor-
relation coefﬁcient 0.042, P = 0.684).TRIB3 protein expression is correlated with breast cancer prognosis
Considering the poor correlation between RNA and protein lev-
els, we assessed whether TRIB3 protein levels were of relevance in
breast cancer patients. Patient characteristics, biological markers
and treatment distribution among the three different groups of
TRIB3 protein expression, negative, weakly positive, or strongly po-
sitive, were similar for most parameters tested (Supplementary Ta-
ble 1). Only a relation of TRIB3 protein with smaller tumor size was
found ({2 P = 0.018). Surprisingly, TRIB3 protein was related to a
good prognosis, which was in direct contrast to the RNA data we
found earlier and have validated above; patients with negative
TRIB3 protein scoring had a mean DFS of 94 (CI = 81–108) months,
with weakly positive scoring had a mean DFS of 108 (CI = 92–123),
whereas the group with a strongly positive expression had a meanDFS of 159 months (CI = 135–182, P = 0.014, Fig. 3A). Similarly, pa-
tients with high TRIB3 protein staining tended to exhibit a better
overall survival (P = 0.058, Fig. 3B). These results were independent
of tumor size, as the prognostic value of TRIB3 protein remained
signiﬁcant after correction for tumor size in a multivariate Cox
regression (not shown).Knockdown of TRIB3 results in improved hypoxia survival of breast
cancer cells
To explore the role of TRIB3 in radiotherapy and/or hypoxia
resistance we performed a colony forming assay using human
breast cancer cells after siRNA mediated TRIB3 knockdown. Surviv-
ing fractions were corrected for plating efﬁciencies of the normoxic
non-irradiated cells (control siRNA 45%, TRIB3 siRNA 1 36% and
TRIB3 siRNA 55%). In MDA-MB-231 cells 4 Gy of X-rays lead to a
surviving fraction of 29% under normoxic conditions. In addition,
48 h of hypoxia lead to a surviving fraction of 6%, which was fur-
ther reduced to 1% when combined with a single fraction of 4 Gy.
After transfection with two different siRNA’s against TRIB3 the sur-
vival rates exhibited a drastic increase, most notably during hypox-
ia (Fig. 4). After TRIB3 knockdown, the survival fractions were 43%
and 30% after 4 Gy under normoxia, whereas under hypoxia 70%
and 87% cell survival was observed, respectively. Survival of cells
with TRIB3 knockdown after 4 Gy under hypoxic conditions in-
creased to 24% and 37%, respectively.Discussion
Here, we validated our earlier results that TRIB3 mRNA expres-
sion denotes a poor prognosis, but unexpectedly also found that
TRIB3 protein – as quantiﬁed with a self-developed, highly speciﬁc
antibody – denoted a good prognosis in human breast cancer pa-
tients. siRNA mediated knockdown experiments show that this is
Fig. 2. TRIB3 protein expression in human breast cancer material. Human breast tumor sections present on the TMA stained for TRIB3. 100magniﬁcation. (A) A section that
was scored as negative, (B) a section that was scored weakly positive, and (C) a section that was scored strongly positive for TRIB3 protein expression.
Fig. 3. TRIB3 protein is correlated with prognosis. Kaplan–Meier plots of breast cancer patients divided into three groups based on their protein expression levels as depicted
in Fig. 3 (negative: closed line, weakly positive: dashed line or strongly positive: dotted line). (A) Disease free survival, (B) overall survival.
Fig. 4. Survival of MDA-MB-231 cells cultured under hypoxia and/or treated with radiotherapy. (A) TRIB3 mRNA expression of MDA-MB-231 cell treated with control siRNA,
TRIB3 siRNA 1 or TRIB3 siRNA 2. (B) Percentage of MDA-MB-231 cell colonies treated with 4 Gy and/or cultured under hypoxic conditions compared to normoxic non-
irradiated colonies. MDA-MB-231 cells were treated with control siRNA, TRIB3 siRNA 1 or TRIB3 siRNA 2.
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press high levels of TRIB3 protein will be more sensitive to hypox-
ia, whereas low TRIB3 expressing tumors are more hypoxia
tolerant. Hypoxia tolerance is an important aspect of tumor pro-gression and treatment efﬁcacy as hypoxia tolerant tumors are less
sensitive to different treatments in breast cancer such as radiother-
apy, which is at least partly under control of the (TRIB3 inducing)
UPR [7].
202 TRIB3 protein and breast cancer prognosisThe protein levels of TRIB3 are regulated by both transcriptional
as well as translational mechanisms. TRIB3mRNA is induced by the
UPR and involves the transcription factor ATF4 [6,26]. In addition,
the NFkB and PI3K pathways induce transcription of TRIB3 [5,26].
Of note, TRIB3 exerts a strong negative feedback loop on the ATF4,
NFkBandPI3Kpathways [12–14,27]. Further,mRNA levels are stabi-
lized by hypoxia-regulated HuR [26]. Interestingly, during anoxia
in vitro protein levels of TRIB3 increase earlier than mRNA levels
[4,27]. This indicates thatnot only transcriptionalbut also additional
hypoxia-associated translational mechanisms regulate TRIB3 pro-
tein levels on a relatively short time scale. Thus the TRIB3 protein
levels, as found in human breast cancer tissue, are the result of a
numberof regulatory feedback loops and temporallydistinct events.
The discrepancy in results considering the described cytoprotective
[13] as well as pro-apoptotic roles of TRIB3 [6] might, consequently,
be caused by the fundamentally different correlations of TRIB3
mRNAandproteinwith tumorphenotype. Furthermore, the fact that
TRIB3 is responsible for the set point in several regulatory feedback
loops could also contribute to these discrepancies.
A great number of studies have used QPCR and/or expression
proﬁling to investigate the role of particular genes in prognosis or
treatment sensitivity of human breast cancer, most notably the
OncotypeDXandMammaprint assays, respectively [27]. Our results
presented here indicate that these data on mRNA levels do not nec-
essarily translate to protein, nor to function, of all genes. Our mRNA
data results, with TRIB3 mRNA being correlated with poor progno-
sis, should be considered indicative of a process that both stimulates
TRIB3 mRNA transcription and/or mRNA stability, and is associated
itself with a poor prognosis. However, caution should be given that
the association of gene ontologies with prognosis or treatment sen-
sitivity cannot function as proof of a functional relation. As such,
much more credence can be given to studies into the association
of (phospho)proteins with prognosis [28].
In conclusion, whereas mRNA levels of TRIB3 are related with a
poor prognosis, TRIB3 protein is associated with a good prognosis
in human breast cancer patients, apparently due to the fact that
TRIB3 is involved in hypoxia and treatment tolerance. Our results
on TRIB3 described here suggest it to be an interesting target for
sensitizing cells to cancer therapy, because modifying the set point
of different intracellular signaling pathways could drastically
change the survival balance of the tumor cells under stressful
microenvironmental circumstances or during treatment.
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